The Economic Times
English EditionEnglish Editionहिन्दी
| 23 October, 2020, 04:51 AM IST | E-Paper
Search
+

    Dr Reddy’s receives DCGI’s approval to conduct clinical trial for Sputnik V vaccine in India

    In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.

    With approvals Sputnik V delivery in India possible by end of 2020: Kirill Dmitriev, CEO, RDIF

    The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund has tied up with India's Dr Reddy’s Laboratories to conduct the clinical trials and distribution of Sputnik V vaccine in India. ET’s Divya Rajagopal caught up with CEO RDIF, Kirill Dmitriev to understand when the vaccine will be available in India. WatchWith approvals Sputnik V delivery in India possible by end of 2020: Kirill Dmitriev, CEO, RDIF

    India trials for Russia's 'Sputnik-V' vaccine could start in next few weeks: Executive

    Indian trials of the Sputnik-V vaccine candidate, being developed by Russia's sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country, Deepak Sapra, CEO for API and pharmaceutical services at Dr. Reddy's, told Reuters.

    Twenty-six scientists question early-stage trial results of Russia's Sputnik-V vaccine

    Twenty-six scientists, most of them working at universities in Italy, have signed an open letter questioning the reliability of the data presented in the early-stage trial results of the Russian COVID-19 vaccine, named "Sputnik-V".

    COVID-19 positivity rate is on decline; India-Russia in talks on Sputnik-V vaccine: Govt

    The Union Health Ministry on Tuesday said though COVID-19 testing has been increased exponentially, there has been a steady decline in the positivity rate and highlighted that the number of active cases of the infection reduced by 6,423 for the first time in a span of 24 hours. Asked whether the Russian government has placed any formal request for the manufacturing of its COVID-19 vaccine in India, Bhushan said as far as the vaccine Sputnik V developed by Russia is concerned, "both the countries (India and Russia) are in communication. Some initial information has been shared while some detailed information is awaited".COVID-19 positivity rate is on decline; India-Russia in talks on Sputnik-V vaccine: Govt

    It is ridiculous to build DRL earnings expectations based on Russia vaccine tieup: Sandip Sabharwal

    ‘ The Russian vaccine is not an approved vaccine and hardly any trials have taken place.’

    Sputnik-V COVID vaccine: Russia's RDIF collaborates with Dr Reddy's Laboratories for trials, distribution

    The Russian Direct Investment Fund has collaborated with Indian pharma giant Dr Reddy's Laboratories to conduct clinical trials of the Sputnik V vaccine against COVID-19 as well as its distribution, RDIF CEO Kirill Dmitriev said on Wednesday. The RDIF is in talks with Indian regulators to ensure that all the requirements for clinical trials are being met, he said.Sputnik-V COVID vaccine: Russia's RDIF collaborates with Dr Reddy's Laboratories for trials, distribution

    RDIF and Dr Reddy's tie up to manufacture coronavirus vaccine Sputnik V for India

    Adding that the platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences.”

    Russia names its coronavirus vaccine as 'Sputnik V' in reference to world's first satellite

    Russia has named its first approved coronavirus vaccine 'Sputnik V' for the foreign markets. It is a reference to the world's first satellite Sputnik and what Moscow sees as its success at becoming the first country to approve a vaccine, a top official said.Russia names its coronavirus vaccine as 'Sputnik V' in reference to world's first satellite

    Days after Russian COVID-19 vaccine trial approval, data breach forces Dr Reddy's plants shut

    In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.

    Mankind pharma collaborates with Russian RDIF for distribution of Sputnik V in India

    Earlier in September, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.

    Second human trials of Russian COVID-19 vaccine abroad, in UAE, have launched - Kremlin

    The trials in the UAE are the second trials of the Sputnik V vaccine abroad, following the launch of trials in Belarus. Trials are also expected to begin in Venezuela in the near future.

    Russia approves second coronavirus vaccine after early trials

    The peptide-based, two-shot vaccine, EpiVacCorona, was developed by the Vector Institute in Siberia and tested among 100 volunteers in early-stage, placebo-controlled human trials, which lasted more than two months and were completed two weeks ago.

    Clinical trial of Sputnik V Coronavirus vaccine to begin this month in countries including India: RDIF

    Russia was in close dialogue with the Indian government and the leading drug manufactures of India regarding the localization of production of Sputnik V vaccine in India.

    Dr Reddy's Laboratories to submit a revised protocol for conducting clinical trials of Russian COVID-19 vaccine

    In a meeting held on Monday, Subject Expert Committee (SEC) on COVID-19 at the CDSCO, deliberated on the application and asked the firm to resubmit a revised protocol as it was not satisfied with the data of Phase II trials submitted by the company, sources told ET.

    Where are we with coronavirus vaccines? Here are the promising nine

    There were several developments regarding vaccines and drugs this week, including the tie-up between the makers of Russia’s Sputnik V vaccine and Dr Reddy’s.

    Panel recommends granting permission to Dr Reddy's for phase 2 trials of Russian COVID vaccine

    The Hyderabad-based pharmaceutical firm had on October 13 reapplied to the Drugs Controller General of India (DCGI) seeking permission to conduct combined phase 2 and 3 human clinical trials of the vaccine in the country.

    Dr Reddy's seeks DCGI nod to conduct phase-3 clinical trial of Russian COVID-19 vaccine

    The Indian pharma giant has collaborated with The Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V as well as its distribution.

    80% jump in 6 months, Covid vaccine can give this stock a shot in the arm

    Opportunity to launch a vaccine would mean one-time exceptional business gain, brand boost

    COVID-19 vaccine: Indian envoy to Russia lauds talks With Russian Direct Investment Fund

    On Tuesday, Russia became the first country in the world to register a vaccine against COVID-19. The vaccine , which is being produced by the Russian Microbiology Research Center Gamaleya, entered Phase 3 of clinical trials on Wednesday.

    Large pharma companies back appeal for TRIPS waiver for Covid-19 cure

    “We endorse the Indian government’s stand asking for a waiver of the TRIPS provisions to deal with the Covid-19 crisis. This is the time for solidarity and global cooperation,” Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, told ET on Sunday.

    48 per cent of Covid-19 deaths reported from 25 districts in eight states: Health Ministry

    Addressing a press briefing, Secretary in the ministry Rajesh Bhushan said the country has recorded the highest number of COVID-19 recoveries in the world at over 56 lakh and conducted the second-highest number of tests at 8.10 crore. "New recoveries have been more than the new cases over the last two weeks. New cases being reported in the last 14 days are below the previous high of 90,000 per day," he said.

    Russia looking for partnership with India for producing COVID-19 vaccine Sputnik: RDIF CEO

    Sputnik V has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology, along with the RDIF. The vaccine has not been tested in Phase 3 or larger clinical trials.

    Market Movers: Pharma steals the show, autos race ahead; 152 stocks flash buy signals

    According to analysts, the market will be trading cautiously this week with a positive bias, with key global events dictating the market movement.

    Vaccine hopes, firm global cues drive Sensex 259 pts higher; Fed policy outcome eyed

    "Benchmark indices ended the day with gains, with most sectoral indices contributing to the rise. However, the continued border tensions and undabated virus infections limited the upmove. Global cues were also positive”, said Vinod Nair, Head of Research at Geojit Financial Services.

    Russian scientist behind COVID-19 vaccine defends 'wartime' roll-out

    Russia has pushed ahead with its potential COVID-19 vaccine at top speed with mass public vaccinations alongside the main human trial, raising concerns among some observers that it was prioritising national prestige over solid science and safety.

    Safety, efficacy main concerns with Russia's COVID-19 vaccine: Nobel laureate Peter Doherty

    Sputnik V has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology along with the Russian Direct Investment Fund (RDIF). The vaccine has not been tested in Phase 3 or larger clinical trials.

    After much fanfare over vaccine, there is now an inexplicable lull in Russia. The reasons are unknown

    The Russian vaccine is one of the nine candidates around the world now in the late-stage clinical trials that are the only sure means to determine whether a vaccine is effective and find possible side effects.

    Amid deepening fears, the story of those who will not wait for superpowers’ Covid vaccines

    The US and other superpowers have laid claim to billions of Covid vaccine doses that are nearing the finish line. That’s sparked worries that poorer countries will be left behind and shots will be slow to reach many of them. Dozens of laboratories, researchers and companies from Thailand to Nigeria are bootstrapping their own work on inoculations.

    The Economic Times
    BACK TO TOP